HCB302

HCB302 is a fusion protein drug candidate developed by HanchorBio for the treatment of neoplasms (cancers). It is currently in preclinical development. The specific mechanism of action, molecular targets, and detailed structure have not been publicly disclosed as of June 2025. However, based on its naming convention and context within the HanchorBio pipeline—which includes other fusion proteins targeting immune checkpoints such as PD-L1, TGF-β, SIRPα/CD47—it is likely that HCB302 represents a novel immunotherapeutic approach for cancer treatment[5]. No clinical trial data or additional mechanistic details are available at this time.